Characteristic | Ki67 CTC-negative patients (no Ki67 + ve CTCs) (%) | Ki67 CTC-positive patients (≥1 Ki67 + ve CTC) (%) |
---|---|---|
Total patient numbers | 28 | 23 |
Age, years | ||
 Median | 79.5 | 72 |
 Range | 63–90 | 52–89 |
Number of metastasic sites | ||
 1 | 12/28 (42.9) | 8/23 (34.8) |
 2 | 10/28 (35.7) | 8/23 (34.8) |
 3+ | 4/28 (14.3) | 7/23 (30.4) |
 Not stated | 2/28 (7.1) | 0/23 (0) |
Metastasic sites | Â | Â |
 Lymph Nodes alone | 0/28 (0) | 0/23 (0) |
 Bone alone | 12/28 (42.9) | 8/23 (34.8) |
 Bone and lymph nodes | 8/28 (28.6) | 5/23 (21.7) |
 Visceral/multiple sites | 6/28 (21.4) | 10/23 (43.5) |
 Unknown/Not stated | 2/28 (7.1) | 0/23 (0) |
Treatment at time of 1st CTC specimen | ||
 Cabazitaxel | 0/28 (0) | 6/23 (23.1) |
 Docetaxel | 6/28 (21.4) | 3/23 (13) |
 Abiraterone | 13/28 (46.4) | 11/23 (47.8) |
 Others/Not stated | 9/28 (32.1) | 3/23 (13) |
Line of treatment at time of 1st CTC specimen | ||
 1 | 5/28 (17.9) | 3/23 (13) |
 2 | 8/28 (28.6) | 5/23 (21.7) |
 3+ | 3/28 (10.7) | 7/23 (30.4) |
 Not stated | 12/28 (42.9) | 8/23 (34.8) |
Previous treatments | ||
 Primary surgery | 5/28 (17.9) | 3/23 (13) |
 Primary radiotherapy | 6/28 (21.4) | 5/23 (21.7) |
 Docetaxel | 21/28 (75) | 20/23 (87) |
 Enzalutamide | 1/28 (3.6) | 0/23 (0) |
 Cabazitaxel | 1/28 (3.6) | 0/23 (0) |
 Abiraterone | 2/28 (7.1) | 5/23 (21.7) |
Total CTC levels at baseline | ||
 Mean | 12.9 | 92.8 |
 Range | 0–79 | 2–316 |